Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention‐deficit/hyperactivity disorder
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: This study examined the effects of atomoxetine ( ATX ) and OROS methylphenidate ( MPH ) on laboratory measures of inhibitory control and attention in youth with attention‐deficit/hyperactivity disorder ( ADHD ). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different mechanisms. Methods: One hundred and two youth (77 male; mean age = 10.5 ± 2.7 years) with ADHD received ATX (1.4 ± 0.5 mg/kg) and MPH (52.4 ± 16.6 mg) in a randomized, double‐blind, crossover design. Medication was titrated in 4–6‐week blocks separated by a 2‐week placebo washout. Inhibitory control and attention measures were obtained at baseline, following washout, and at the end of each treatment using Conners' Continuous Performance Test II ( CPT ‐ II ), which provided age‐adjusted T ‐scores for reaction time ( RT ), reaction time variability ( RT variability), and errors. Repeated‐measures analyses of variance were performed, with Time (premedication, postmedication) and Treatment type ( ATX , MPH ) entered as within‐subject factors. Data from the two treatment blocks were checked for order effects and combined if order effects were not present. Clinical trial registration: Clinicaltrials.gov: NCT 00183391. Results: Main effects for Time on RT ( p = .03), RTSD ( p = .001), and omission errors ( p = .01) were significant. A significant Drug × Time interaction indicated that MPH improved RT , RTSD , and omission errors more than ATX ( p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms. Conclusions: MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD . However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD is indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Vaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 2×
“In addition, MPH increases activity in caudate (Vaidya et al., 1998) due to its effect of binding to dopamine transporters (Volkow et al.”
BackgroundMorón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617 · cited 1×
“However, whereas stimulants enhance dopamine neurotransmission in striatum and a variety of other brain regions, the effects of ATX on dopamine are selective to prefrontal cortex (Berridge et al., 2006; Bymaster et al., 2002; Moron, Brockington, Wise, Rocha, & Hope, 2002).”
BackgroundMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 1×
“Atomoxetine (ATX), a US Food and Drug Administration (FDA) approved nonstimulant medication for ADHD, has demonstrated efficacy in reducing ADHD symptoms in numerous controlled trials (Michelson et al., 2002).”
BackgroundSelf-citationComparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 1×
“Further, the effect sizes for CPT-measured cognitive improvements with MPH here are in agreement with previous reviews that demonstrate smaller effects on cognitive function than on behavior (Faraone & Buitelaar, 2010; Pietrzak et al., 2006).”
ResultSprague, R. L., & Sleator, E. K. (1977) · Science · doi:10.1126/science.337493 · Cited by 441 · cited 1×
“…had received considerable attention and some empirical support in an influential early study examining single challenge dose effects of amphetamine (Sprague & Sleator, 1977), but this finding is generally not considered in the current approach to titrating stimulants – which is based primarily on…”
BackgroundLosier, B. J., McGrath, P. J., & Klein, R. M. (1996) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.1996.tb01494.x · Cited by 424
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 2×
“Similar to stimulants, ATX is an inhibitor of the norepinephrine transporter (NET), which increases extracellular concentrations of norepinephrine diffusely and dopamine in prefrontal cortex (Bolden-Watson & Richelson, 1993; Gatley, Pan, Chen, Chaturvedi, & Ding, 1996; Newcorn et al., 2008).”
BackgroundSelf-citationVolkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321 · cited 1×
“In addition, MPH increases activity in caudate (Vaidya et al., 1998) due to its effect of binding to dopamine transporters (Volkow et al., 2002), yet ATX should not have direct effects in caudate as there are few norepinephrine transporters in this region.”
Background
Cited by
Adult attention-deficit hyperactivity disorder: key conceptual issues
Asherson, P., Buitelaar, J., Faraone, S. V., & Rohde, L. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30032-3 · Cited by 347
Linking ADHD to the Neural Circuitry of Attention
Mueller, A., Hong, D. S., Shepard, S., & Moore, T. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.03.009 · Cited by 158
Kowalczyk, O. S., Cubillo, A. I., Smith, A., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.139 · Cited by 63
Griffiths, K. R., Leikauf, J. E., Tsang, T. W., Clarke, S., Hermens, D. F., Efron, D., Williams, L. M., & Kohn, M. R. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.03.009 · Cited by 29
To Prescribe or Not? Pharmacological Options in Adult Attention-Deficit/Hyperactivity Disorder
Aoshima-Kilroy, A., Banu, S., Udoetuk, S., Shah, A. A., & Moukaddam, N. (2017) · Psychiatric Annals · doi:10.3928/00485713-20170510-01 · Cited by 1
Metadata
- Authors
- Bédard, A. V., Stein, M. A., Halperin, J. M., Krone, B., Rajwan, E., & Newcorn, J. H.
- Venue
- Journal of Child Psychology and Psychiatry
- Publisher
- Wiley
- Published
- 2014-06-19
- Volume
- 56
- Issue
- 1
- Pages
- 40-48
- ISSN
- 0021-9630 (ISSN-L)
- 1469-7610
- OpenAlex
- W1969779240
- Cited by
- 61
- References
- 26
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention‐deficit/hyperactivity disorder. https://app.cochat.ai/papers/10.1111/jcpp.12272
- The paper
- Bédard, A. V., Stein, M. A., Halperin, J. M., Krone, B., Rajwan, E., & Newcorn, J. H. (2015). Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention‐deficit/hyperactivity disorder. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/jcpp.12272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.